CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.05
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$8.15

04 Sep
2026

-0.110

OPEN

$8.26

-1.33%

HIGH

$8.26

112,579

LOW

$8.11

TARGET
$10.75 31.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 67.8 65.4 xxx
DPS (cps) xxx 5.0 6.0 xxx
EPS Growth xxx - 6.1% - 3.6% xxx
DPS Growth xxx 0.0% 20.0% xxx
PE Ratio xxx N/A 12.5 xxx
Dividend Yield xxx N/A 0.7% xxx
Div Pay Ratio(%) xxx 7.4% 9.2% xxx

Dividend yield today if purchased 3 years ago: 0.30%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.61

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 5.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx67.8
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx94.0 M
Book Value Per Share xxxxxxxxxxxxxxx541.1
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx36.07 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx13.21 %
Return on Invested Capital xxxxxxxxxxxxxxx13.16 %
Return on Assets xxxxxxxxxxxxxxx11.93 %
Return on Equity xxxxxxxxxxxxxxx13.21 %
Return on Total Capital xxxxxxxxxxxxxxx15.74 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx32.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx252 M
Price To Book Value xxxxxxxxxxxxxxx1.90

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx1.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx18 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

28/08/2026

3

Downgrade to Speculative Hold from Buy

$11.50

41.10%

Bell Potter cuts its target for Clinuvel Pharmaceuticals to $11.50 from $17.00 after FY26 results and downgrades to Speculative Hold from Buy.

FY26 revenue fell -1% to $94.0m, while underlying earnings (EBITDA) declined -2% to $41.5m, both below the broker's forecasts for $98.3m and $42.2m, respectively.

US Scenesse sales fell -15%, with competitive pressure emerging from US-listed biotechnology company Disc Medicine's expanded access program for bitopertin, the analysts explain.

FY27-FY29 profit forecasts fall by -$3m, -$6m and -$11m, respectively, reflecting lower Scenesse sales assumptions.

Bell Potter views December's Phase III vitiligo trial readout as increasingly pivotal to Clinuvel's growth outlook.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 5.00 cents and EPS of 61.80 cents.
Bell Potter forecasts a full year FY28 dividend of 5.00 cents and EPS of 52.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

30/08/2026

3

Downgrade to Hold from Buy

$9.52

16.81%

Canaccord Genuity downgrades its rating for Clinuvel Pharmaceuticals to Hold with its target price decreased to $9.52 from $27.90 following an FY26 result featuring revenue of $94.0m and EBITDA of $40.5m.

The analyst views the core EPP business as exhibiting flat growth amid emerging competition, while noting significant pipeline opportunities in vitiligo and ACTH remain long-dated.

The company closed FY26 with $252.1m in cash reserves and declared a 5.0c dividend.

The revised valuation framework applies a lower 3.5x EBITDA multiple to the EPP franchise and reduces the probability of success assumption for the vitiligo asset to 31%.

The analyst anticipates topline results from the Phase III CUV105 vitiligo trial in December 2026 will present a near-term catalyst for investors.

FORECAST
Canaccord Genuity forecasts a full year FY27 dividend of 5.00 cents and EPS of 81.00 cents.
Canaccord Genuity forecasts a full year FY28 dividend of 5.00 cents and EPS of 83.00 cents.
Access Extra Coverage Research History >

CUV STOCK CHART

FNArena News on CUV

1
Weekly Ratings, Targets, Forecast Changes – 04-09-26

Sep 07 2026 - Weekly Reports
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 04-09-26

Sep 04 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Sep 01, 2026

Sep 01 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 31, 2026

Aug 31 2026 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 28-08-26

Aug 31 2026 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps